Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 964-973

  Jain, Pramod T ^a,b   Rajah, Talitha T ^a   Pento, J Thomas ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analog II; Anticancer drug; Breast cancer; Cyclopropyl antiestrogens; MCF 7; MDA MB 231

Indexed keywords

1,1 DICHLORO 2,3 DIARYLCYCLOPROPANE; 1,1 DICHLORO 2,3 DIPHENYLCYCLOPROPANE; ANTIESTROGEN; ESTRADIOL; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 0031455519     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00008     Document Type: Article

References (35)

1. Lemer L, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990; 50: 4177-89.
2. Laymann SD, Jordan VC. Possible mechanisms tor the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxitriphetol) in the mouse uterus. Biochem Pharmacol 1985; 34: 2795-806.
3. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 1978; 253: 2223-8.
4. Westley B, May FE, Brown MC, et al. Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF-7 cells and two tamoxifen-resistant sublines. J Biol Chem 1984; 259: 10030-5.
5. May FEB, Westley BR. Effects of tamoxifen and hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells. J Biol Chem 1987; 262: 15894-9.
6. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996; 88: 832-4.
7. Fornander T, Cedermark B, Mattsson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; i: 117-9.
8. Gottardis MM, Robinson SP, Jordan VC. Estradiol stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 30: 311-4.
9. Osborne CK, Coronado EB, Robinson JR. Human breast cancer in athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987; 23: 1189-96.
10. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumor in athymic mouse after long-term tamoxifen administration. Cancer Res 1988; 48: 5183-8.
11. Pento JT, Magarian RA, Wright RJ, King MM, Benjamin EJ. Non-steroidal estrogens and antiestrogens: biological activity of cyclopropyl analogs of stilbene and stilbenediol. J Pharm Sci 1981; 70: 399-403.
12. Griffin MT, Pento JT, Magarian RA, Mousissian GK, Basmajian GP. Biodistribution of a novel antiestrogen (Analog II) in the mouse and rat. Endocrine Res 1990; 16: 269-82.
13. Pento JT, Magarian RA, King MM. A comparison of efficacy for antitumor activity of non-steroidal antiestrogen Analog II and tamoxifen in 7,12-dimethylbenz(α)anthracene-induced rat mammary tumors. Cancer Lett 1982; 15: 261-9.
14. King MM, Pento JT, Magarian RA. The interaction of dietary fat and antiestrogen treatment on DMBA-induced mammary tumors in the rat. Nutrition Cancer 1985; 7: 239-49.
15. King MM, Magarian RA, Terao J, Brueggmann G. Effect of nonsteroidal antiestrogen, Analog II and tamoxifen on a metastatic transplantable rat mammary tumor. J Natl Cancer Inst 1985; 74: 447-51.
16. Jain PT, Pento JT. A vehicle for the evaluation of hydrophobic compounds in cell culture. Res Commun Chem Pathol Pharmacol 1991; 74: 105-16.
17. Jain PT, Pento JT, Magarian RA. A comparison of the antitumor activity of two cyclopropyl antiestrogens (4d and 5c) on human breast cancer in culture. Anti-Cancer Drugs 1994; 5: 429-36.
18. Stoessel S, Leclercq G. Competitive binding assay for estrogen receptor in monolayer culture: measure of receptor activation potency. J Steroid Biochem 1987; 25: 677-82.
19. Jain PT, Pento JT, Magarian RA. Influence of cyclopropyl antiestrogens on the cell cycle kinetics of MCF-7 human breast cancer cells. Anticancer Res 1995; 15: 2529-32.
20. Lin X, Dashti A, Schinazi RF, Tang J. Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. J FASEB 1993; 7: 1070-80.
21. Vie P, Vignon F, Derocq D, Rochefort H. Effect of estradiol on the ultrastructure and growth of MCF-7 cells in culture. Cancer Res 1982; 42: 667-73.
22. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 humn breast cancer cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 1983; 43: 3998-4005.
23. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
24. Gulino A, Barrera G, Vacca A, et al. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res 1986; 46: 6274-8.
25. Gundimedia U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen-negative breast cancer cells. J Biol Chem 1996; 271: 13504-14.
26. Bardon S, Vignon F, Montcourrier P, Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and antiprogestin in breast cancer cells. Cancer Res 1987; 47: 1441-8.
27. Haar ET, Day BW. Cytostatic and cytotoxic action of Z1-, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines. Anticancer Res 1996; 16: 1107-16.
28. Reddel RR, Murphy LC, Hall RE, Sutherland RL. Differential sensitivity of human breast cancer cell-lines to the growth inhibitory effects of tamoxifen. Cancer Res 1985; 45: 1525-31.
29. Murphy LC, Sutherland RL. Differential effects of tamoxifen and analogs with non-basic side chains on cell-proliferation in vitro. Endocrinology 1985; 116: 1071-8.
30. Antalky T, Pelletier G, Zeytinoglu F, Labrie F. Changes of morphology and prolactin secretion induced by 2-Br-α-ergocryptine estradiol, and thyrotropin-releasing hormone in rat anterior pituitary cells in culture. J Cell Biol 1980; 86: 377-87.
31. Yates J, King RJB. Correlation of growth properties and morphology with hormone responsiveness of mammary tumor cells in culture. Cancer Res 1981; 41: 258-62.
32. Pento JT, Rajah TT, Abidi SMA, Hurt GM. Influence of antiestrogens and growth factors on the invasiveness of breast cancer cells in culture. Keystone Symposium on Molecular and Cellular Biology: Cancer Cell Invasion and Motility. J Cell Biochem 1995; S19B, 413.
33. Mathew A, Rajah TT, Hurt GM, Abidi SMA, Dmytryk JJ, Pento JT. Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model. Clin Exp Metastasis, 1997; 15: 393-9.
34. Rajah TT, Pento JT. Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells. Cancer Invest; in press.
35. Abidi SMA, Howard EW, Dmytryk JJ, Pento JT. Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis 1997; 15: 432-9.